论文部分内容阅读
目的研究在胃癌治疗中实行贝伐单抗联合化疗治疗的临床效果以及有效性。方法 62例胃癌患者,依据患者入院就诊时间随机分为参照组与实验组,各31例。参照组患者予以单纯化疗,实验组患者予以贝伐单抗与化疗联合治疗,比较两组患者治疗的临床效果。结果实验组患者总有效率为96.77%,显著高于参照组的74.19%,差异具有统计学意义(χ~2=6.3690,P<0.05);实验组不良反应发生率为38.71%,稍高于参照组的25.80%,但差异无统计学意义(χ~2=1.1810,P>0.05)。结论将贝伐单抗与化疗联合治疗应用在胃癌治疗中具有显著效果,可提升总有效率,改善治疗效果,且不良反应可耐受,具有临床应用价值。
Objective To study the clinical efficacy and effectiveness of bevacizumab combined with chemotherapy in the treatment of gastric cancer. Methods Totally 62 cases of gastric cancer patients were randomly divided into reference group and experimental group according to the time of hospital admission, each of 31 cases. The patients in the reference group were treated with chemotherapy alone. The patients in the experimental group were treated with bevacizumab plus chemotherapy, and the clinical effects of the two groups were compared. Results The total effective rate of the experimental group was 96.77%, which was significantly higher than that of the reference group (74.19%), the difference was statistically significant (χ ~ 2 = 6.3690, P <0.05). The incidence of adverse reactions in the experimental group was 38.71% The reference group of 25.80%, but the difference was not statistically significant (χ ~ 2 = 1.1810, P> 0.05). Conclusion The combined application of bevacizumab and chemotherapy has a significant effect in the treatment of gastric cancer, which can improve the total effective rate, improve the therapeutic effect, and the adverse reaction is tolerable, which has clinical value.